NF2 BioSolutions funded the preclinical research of Dr. Brenner and Dr. Mekalanos and it led to the creation of the biotech Mulberry Biotherapeutics. NF2 BioSolutions is supporting MulberryBio to make sure they will succeed in establishing a clinical trial and developing a drug for NF2 patients and patients suffering from sporadic Schwannomas.

In this session, hear from Dr. Neil Kirby (CEO of Mulberry) and Dr. Brenner (Co funder of Mulberry). They shared with us the status of this project, its applications, and future steps.

How to activate the captions?

Click on the "CC" button to activate captions in English.

To auto-translate captions to your language follow these instructions:

1. Click on the Settings cog

2. Then click on "Subtitles"

3. Choose the option to auto translate

4. Choose your preferred language

Q&A